CASE REPORT

Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA

Susumu Takeuchi, Toshihiro Obayashi, Junji Toyama

Abstract

A 20 year old man with severe chest pain was hospitalised for acute myocardial infarction. Coronary angiography revealed total obstruction of his right coronary artery, which was successfully recanalised by direct percutaneous transluminal coronary angioplasty (PTCA). There was also diffuse thrombi in the left coronary artery that was not recanalised by perfusion with 3000 U pro-urokinase. Anticoagulant therapy was performed after PTCA. Creatine kinase peaked one day after hospitalisation (4805 U/l). The activated partial thromboplastin time was 62.6 seconds (45%). Plasma anticardiolipin IgG antibodies were high (3.8 and 2.7) in repeated examinations. The PTCA site was patent after three months. Primary antiphospholipid syndrome should be considered as a cause of acute myocardial infarction in young adults, and PTCA with anticoagulant treatment is effective for initial treatment of the syndrome.

(Heart 1998;79:96-98)

Keywords: primary antiphospholipid syndrome; acute myocardial infarction; percutaneous transluminal coronary angioplasty

Antiphospholipid syndrome is a thrombotic disorder characterised by antiphospholipid antibodies. Clinical features are thromboses,

thrombocytopenia, and recurrent fetal loss.¹ Patients with antiphospholipid syndrome often exhibit positive lupus anticoagulant activity but they infrequently suffer from the typical systemic lupus erythematosus (SLE) that satisfies diagnostic criteria. Thus, antiphospholipid syndrome without clinical features of SLE is called primary antiphospholipid syndrome.² We report a case of primary antiphospholipid syndrome that was initiated by acute myocardial infarction without any other thrombotic disorders.

Case report

A 20 year old man with a three month history of chest pain was admitted to our hospital because of severe chest pain and vomiting. He had no risk factors for atherosclerosis (diabetes mellitus, hyperlipidaemia, hypertension). On examination his face was pale, and systolic murmur was audible at the apex. ECG showed ST segment elevation in II, III, aVF, and V6, and ST depression in I, aVL, V5. We diagnosed acute myocardial infarction and performed emergent coronary angiography. The right coronary artery was obstructed totally, therefore, he underwent PTCA with successful recanalisation (fig 1). Although 75% stenosis remained immediately after the PTCA, we finished the PTCA because this stenotic lesion was considered to be caused by thrombi. The left anterior descending artery, diagonal branches, and septal branch all had diffuse linear defects of contrast medium, suggesting multiple thrombi. A bolus injection of pro-urokinase (3000 U) to the left coronary artery was unsuccessful. Intravenous heparin (15 000 U/day) infusion was performed for the next 10 days, followed by warfarin. Thrombo test was maintained about 25% by oral warfarin (3.5 mg/day). No bleeding complications were noted during thrombolytic and anticoagulation treatment. Serum creatine kinase peaked (4805 U/l) 10 hours after PTCA. Congestive heart failure was controlled by diuretics, nitrate, and low dose dopamine.

The angiography finding of multiple thrombi prompted haematological tests for thrombotic disorders. Blood platelet count was 93 000/ml and prothrombin time was normal (10.3 seconds), but activated partial thromboplastin time was prolonged (62.6 seconds). Anti-DNA antibody was 320 times, but antinuclear

Department of Cardiology, Kariya General Hospital, Kariya City, Japan
S Takeuchi
T Obayashi

Department of Circulation, Research Institute of Environmental Medicine, Nagoya University, Nagoya City, Japan
J Toyama

Correspondence to:
Dr Takeuchi, Department of Cardiology, Kariya General Hospital, 5-15, Sumiyoshi-Cho, Kariya City, Aichi Prefecture, Japan.

Accepted for publication
28 August 1997

Figure 1 Right coronary arteriogram on admission shows total obstruction of right coronary artery (a). Arteriogram after PTCA shows successful recanalisation. There is diffuse thrombi in the coronary artery (b).

Figure 2 Left coronary arteriogram after three months shows diffuse organising thrombi in left anterior descending artery (arrows).

antibody was negative. Lupus anticoagulant was positive, biological syphilis test was negative, and IgG anticardiolipin antibody was 3.8 (normal < 1.0). However, there were no signs nor symptoms of multiple thrombosis or SLE.

Angiography at three months revealed no stenotic lesion or thrombus in right coronary artery. However, in the left anterior descending artery the linear defects suggesting organised thrombi still existed (fig 2). Left ventriculography revealed that the left ventricle was dilated and severely hypokinetic. Left ventricular diastolic internal dimension was 6.78 cm, left ventricular systolic internal dimension 5.02 cm, and echocardiography showed an ejection fraction of 0.50. Lupus anticoagulant was still positive and IgG anticardiolipin antibody was 2.7. Antiphospholipid antibodies tests repeated three months apart remained positive. These findings satisfy the criteria for diagnosis of antiphospholipid syndrome by Harris,³ and thus he was diagnosed with primary antiphospholipid syndrome because he had no typical signs of SLE.

Table 1 Case reports of antiphospholipid syndrome with acute myocardial infarction

Case	Reference	Age	Sex	Lesion	Treatment	Other thrombosis
1	Harpaz <i>et al</i> ⁵	40	M	Anterior	t-PA (iv)	Pulmonary embolism amaurosis fugax
2	Kattwinkel <i>et al</i> ⁶	29	F	Diffuse	Conservative	Not described (recurrent fetal loss)
3	Thorp <i>et al</i> ⁷	29	F	Inferior	Conservative	DVT
4	Miller <i>et al</i> ⁸	8	F	Lateral	Resuscitation death	Not described
5	Ho <i>et al</i> ⁹	62	M	Anterior	t-PA (iv)	DVT
6	Sakakibara <i>et al</i> ¹⁰	32	F	Inferior	Conservative CABG	Cerebral infarction
7	Chambers <i>et al</i> ¹¹	56	F	Inferior	Streptokinase (iv) PTCA CABG	Not described
8	Kovacs <i>et al</i> ¹²	56	F	Diffuse	t-PA (iv)	DVT
9	Derksen <i>et al</i> ¹³	32	F	Anterior	Conservative	DVT

t-PA, tissue plasminogen activator; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; DVT, deep vein thrombosis.

The patient was admitted twice in the following few years because of congestive heart failure but he has not developed further thrombotic disorder.

Discussion

The most common features of thrombotic disorders in antiphospholipid syndrome are deep vein thrombosis, pulmonary thromboembolism, and stroke. Their occurrence is often multiple and repeated, but this syndrome is rarely initiated in the coronary arteries. According to Asherson *et al*, nine of 13 antiphospholipid syndrome patients with myocardial infarction had previous recurrent deep vein thromboses; only one patient had myocardial infarction before any evidence of vascular occlusion.⁴ Table 1 shows reports of cases of antiphospholipid syndrome with acute myocardial infarction since the report by Harris.⁵⁻¹³ In three of nine patients with antiphospholipid syndrome and myocardial infarction there was no description as to whether there were other thrombotic disorders, except case 2 who experienced four spontaneous fetal losses. One of the mechanisms of fetal loss in antiphospholipid syndrome is suspected infarction of the placenta due to thrombus. Therefore, we cannot confirm that any of these patients have primary antiphospholipid syndrome with myocardial infarction but no other thrombotic disorder.

Widespread cardiac dysfunctions due to multiple arteriolar thrombi are reported in cases of antiphospholipid syndrome even with normal valves and coronary arteries.¹⁴ Case 2 had diffuse ST segment depression and global dysfunction of left ventricle with some segmental heterogeneity in echocardiographic examination. A right ventricular endomyocardial biopsy of this patient revealed multiple small vessel occlusion due to thrombi. The echocardiographic examination of case 8 disclosed that basal segments were normal but mid and apical lesions were akinetic to dyskinetic, suggesting the existence of intramyocardial thrombosis. The left ventriculography of our case revealed a severe diffuse hypokinesia in association with akinesia in the area of myocardial infarction, suggesting the existence of more diffuse intramyocardial thrombi.

The trial of PTCA for the coronary occlusion of antiphospholipid syndrome was unsuccessful (table 1, case 7), and coronary bypass was performed in this case. It seems we are the first to succeed in using direct PTCA for antiphospholipid syndrome with myocardial infarction. We confirmed that the PTCA site was still patent three months later. Anticoagulant therapy commenced immediately after the PTCA may have contributed to such long term coronary patency. In the left coronary artery there were many thrombi so we also injected pro-urokinase (3000 U) as the thrombi were diffuse. Harpaz *et al* and Ho *et al* successfully used intravenous thrombolytic treatments in cases 1 and 5 (table 1).^{5,9} Thus thrombolysis may be effective as initial treatment for acute thrombotic disorder including acute myocardial infarction. In our case, we assumed that

thrombi in the left coronary artery had already been organised when emergent angiography was carried out. If thrombi are thought to be organised, intracoronary thrombolysis is ineffective.

Acute myocardial infarction is unusual in young adults, but it has been reported in patients with antiphospholipid syndrome. In conclusion, when young patients with acute myocardial infarction are examined, we should perform immunological tests (lupus anticoagulant, anticardiolipin antibodies, etc) and examination of thromboses of multiple organs. In such a case, PTCA is effective if it is followed by anticoagulant therapy.

- 1 Hughes GRV, Harris NN, Gharavi AE. The anticardiolipin syndrome. *J Rheumatol* 1986;13:486-9.
- 2 Asherson RA. A "primary" antiphospholipid syndrome. *J Rheumatol* 1988;15:1742-6.
- 3 Harris EN. Antiphospholipid antibodies. *Br J Haematol* 1990;74:1-9.
- 4 Asherson RA, Khamashta MA, Baguley E, Oakley CM, Rowell NR, Hughes GRV. Myocardial infarction and antiphospholipid antibodies in SLE and related disorder. *Q J Med* 1989;73:1103-15.
- 5 Harpaz D, Glikson M, Sidi Y, Hod H. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. *Am Heart J* 1991;122:1492-5.
- 6 Kattwinkel N, Villanueva AG, Labib SB, Aretz HT, Walek JW, Burns DL, et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. *Ann Intern Med* 1992;116:974-6.
- 7 Thorp JJ, Chescheir NC, Fann B. Postpartum myocardial infarction in a patient with antiphospholipid syndrome. *Am J Perinatol* 1994;11:1-3.
- 8 Miller DJ, Maisch SA, Perez MD, Kearney DL, Feltes TF. Fatal myocardial infarction in an 8-year-old girl with systemic lupus erythematosus, Raynauds phenomenon, and secondary antiphospholipid syndrome. *J Rheumatol* 1995;22:768-73.
- 9 Ho YL, Chen MF, Wu CC, Chen WJ, Lee YT. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid syndrome. *Cardiology* 1996;87:354-7.
- 10 Sakakibara N, Kawasuji M, Matsumoto Y, Takemura H, Watanabe Y. Coronary artery bypass grafting in a patient with antiphospholipid syndrome. *Ann Thorac Surg* 1996;61:739-40.
- 11 Chambers JDJ, Haire WD, Deligonul U. Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. *Am Heart J* 1996;132:189-90.
- 12 Kovacs KA, Burggraf GW, Dewar CL. Reversible cardiogenic shock in an angry woman—case report and review of the literature. *Can J Cardiol* 1996;12:689-93.
- 13 Derksen RH, Gmelig-Meijling FH, de Groot PG. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. *Lupus* 1996;5:77-80.
- 14 Kaplan SD, Chartash EK, Pizzarello RA, Furie RA. Cardiac manifestations of the antiphospholipid syndrome. *Am Heart J* 1992;124:1331-8.